← Back to front page
United States · Platforms & data · Benzinga

Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study

Published by Benzinga · United States 2 h ago
Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study
Benzinga

Detailed summary

Lexeo Therapeutics Inc. (NASDAQ:LXEO) on Monday announced positive interim results from its ongoing HEROIC-PKP2 Phase 1/2 trial evaluating LX2020 in PKP2 arrhythmogenic…

Read the full article on Benzinga Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.benzinga.com)

Also worth reading